XML 33 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Bioniz
Common Stock
Common Stock
Bioniz
Additional Paid-in Capital
Additional Paid-in Capital
Bioniz
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at Dec. 31, 2020 $ 69,854   $ 2   $ 141,074   $ (297) $ (70,925)
Balance, Shares at Dec. 31, 2020     24,753,102          
Issuance of common stock from follow-on offering, net of issuance costs 29,909       29,909      
Issuance of common stock from follow-on offering, net of issuance costs,Shares     4,285,710          
Issuance of common stock under employee stock purchase plan 261       261      
Issuance of common stock under employee stock purchase plan, Shares     90,402          
Exercise of stock options 891       891      
Exercise of stock options, Shares     326,454          
Vesting of restricted stock liability 73       73      
Stock-based compensation expense 4,410       4,410      
Comprehensive income 159           159  
Net loss (39,052)             (39,052)
Balance at Dec. 31, 2021 66,505   $ 2   176,618   (138) (109,977)
Balance, Share at Dec. 31, 2021     29,455,668          
Issuance of common stock   $ 22,542   $ 1   $ 22,541    
Issuance of common stock, Shares       4,820,230        
Issuance of common stock under employee stock purchase plan 215       215      
Issuance of common stock under employee stock purchase plan, Shares     138,251          
Vesting of restricted stock liability 53       53      
Stock-based compensation expense 4,841       4,841      
Comprehensive income 214           214  
Net loss (62,428)             (62,428)
Balance at Dec. 31, 2022 $ 31,942   $ 3   $ 204,268   $ 76 $ (172,405)
Balance, Share at Dec. 31, 2022     34,414,149